Vascular Biogenics (NASDAQ:VBLT) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.
Several other equities analysts have also recently weighed in on VBLT. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Vascular Biogenics in a report on Thursday, May 16th. Oppenheimer assumed coverage on Vascular Biogenics in a research note on Thursday, June 27th. They issued an “outperform” rating and a $2.00 target price on the stock. Zacks Investment Research cut Vascular Biogenics from a “buy” rating to a “hold” rating in a research note on Thursday, May 30th. CIBC assumed coverage on Vascular Biogenics in a research note on Thursday, June 27th. They issued an “outperform” rating on the stock. Finally, Chardan Capital restated a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Thursday, May 16th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Vascular Biogenics currently has an average rating of “Buy” and an average price target of $2.38.
Shares of NASDAQ:VBLT traded down $0.01 during trading on Thursday, hitting $1.28. 3,401 shares of the company’s stock traded hands, compared to its average volume of 42,376. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $1.90. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.05. The firm has a market cap of $45.93 million, a P/E ratio of -2.06 and a beta of -0.33. The firm has a 50-day simple moving average of $1.30.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.06). Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%. The business had revenue of $0.22 million for the quarter, compared to the consensus estimate of $2.30 million. Equities analysts forecast that Vascular Biogenics will post -0.53 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Athena Capital Advisors LLC bought a new stake in Vascular Biogenics in the 1st quarter valued at approximately $25,000. Menta Capital LLC bought a new stake in Vascular Biogenics in the 1st quarter valued at approximately $35,000. Finally, First Republic Investment Management Inc. lifted its stake in Vascular Biogenics by 7.4% in the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 6.85% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
See Also: How does the Federal Reserve determine interest rates?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.